Auto-induction of phase i and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Zang, Meitong ^a   Zhu, Fanping ^a   Li, Xinxiu ^a   Yang, Aijuan ^a   Xing, Jie ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Artemisinin; Auto induction metabolism; CYP activity; Healthy Chinese

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ PLUS PIPERAQUINE; ARTEQUICK; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; CYTOCHROME P450 3A; DRUG COMBINATION; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG AUTOINDUCTION METABOLISM; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; REPEATED DRUG DOSE; TANDEM MASS SPECTROMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CHEMISTRY; DRUG COMBINATION; METABOLISM; ORAL DRUG ADMINISTRATION; PLASMA;

ADMINISTRATION, ORAL; ADULT; ARTEMISININS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP3A; DRUG COMBINATIONS; HUMANS; PLASMA; QUINOLINES; TANDEM MASS SPECTROMETRY;

EID: 84902547173     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-214     Document Type: Article

References (27)

1. A concise synthesis of (+)-artemisinin. Zhu C, Cook SP, J Am Chem Soc 2012 134 13577 13579 10.1021/ja3061479 22866604
2. High-level semi-synthetic production of the potent antimalarial artemisinin. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, McPhee D, Leavell MD, Tai A, Main A, Eng D, Polichuk DR, Teoh KH, Reed DW, Treynor T, Lenihan J, Fleck M, Bajad S, Dang G, Dengrove D, Diola D, Dorin G, Ellens KW, Fickes S, Galazzo J, Gaucher SP, Geistlinger T, Henry R, Hepp M, Horning T, Iqbal T, et al. Nature 2013 496 528 532 10.1038/nature12051 23575629
3. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Salman S, Page-Sharp M, Batty KT, Kose K, Griffin S, Siba PM, Ilett KF, Mueller I, Davis TM, Antimicrob Agents Chemother 2012 56 3288 3297 10.1128/AAC.06232-11 22470119
4. Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Krudsood S, Tangpukdee N, Thanchatwet V, Wilairatana P, Srivilairit S, Pothipak N, Jianping S, Guoqiao L, Brittenham GM, Looareesuwan S, Southeast Asian J Trop Med Public Health 2007 38 971 978 18613536
5. Isolation and identification of the metabolite of artemisinin in human (in Chinese). Zhu DY, Huang BS, Chen ZL, Yin ML, Yang YM, Dai ML, Wang BD, Huang ZH, Zhongguo Yao Li Xue Bao 1983 4 194 197 6228121
6. Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Svensson US, Mäki-Jouppila M, Hoffmann KJ, Ashton M, Biopharm Drug Dispos 2003 24 71 85 10.1002/bdd.342 12619052
7. Rapid identification of phase I and II metabolites of artemisinin antimalarials using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange technique. Liu T, Du F, Wan Y, Zhu F, Xing J, J Mass Spectrom 2011 46 725 733 10.1002/jms.1943 21766391
8. Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Hien TT, Hanpithakpong W, Truong NT, Dung NT, Toi PV, Farrar J, Lindegardh N, Tarning J, Ashton M, Clin Ther 2011 33 644 654 10.1016/j.clinthera.2011.04.017 21665048
9. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Niêu NT, Công LD, Drug Metab Dispos 1998 26 25 27 9443848
10. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M, Antimicrob Agents Chemother 2002 46 1026 1031 10.1128/AAC.46.4.1026-1031.2002 11897585
11. In vitro evidence for auto-induction of artemisinin metabolism in the rat. Gupta S, Svensson US, Ashton M, Eur J Drug Metab Pharmacokinet 2001 26 173 178 10.1007/BF03190393 11695717
12. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M, Clin Pharmacol Ther 2003 74 32 43 10.1016/S0009-9236(03)00092-4 12844133
13. Evaluation of CYPs inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Xing J, Kirby BJ, Whittington D, Wan Y, Goodlett DR, Drug Metab Dispos 2012 40 1757 1764 10.1124/dmd.112.045765 22679214
14. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Svensson US, Ashton M, Br J Clin Pharmacol 1999 48 528 535 10583023
15. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM, Eur J Clin Pharmacol 2003 59 429 442 10.1007/s00228-003-0636-9 12920490
16. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson US, Ashton M, Fundam Clin Pharmacol 2007 21 307 316 10.1111/j.1472-8206.2007.00471.x 17521300
17. Artemisinin induces omeprazole metabolism in human beings. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, Nguyen TN, Nguyen DS, Lykkesfeldt J, Le DC, Clin Pharmacol Ther 1998 64 160 167 10.1016/S0009-9236(98) 90149-7 9728896
18. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Mihara K, Svensson US, Tybring G, Hai TN, Bertilsson L, Ashton M, Fundam Clin Pharmacol 1999 13 671 675 10.1111/j.1472-8206.1999. tb00379.x 10626755
19. Artemisinin and CYP2A6 activity in healthy subjects. Asimus S, Hai TN, Van Huong N, Ashton M, Eur J Clin Pharmacol 2008 64 283 292 10.1007/s00228-007- 0406-1 18064444
20. Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms. Burk O, Piedade R, Ghebreghiorghis L, Fait JT, Nussler AK, Gil JP, Windshügel B, Schwab M, Br J Pharmacol 2012 167 666 681 10.1111/j.1476-5381.2012.02033.x 22577882
21. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Kenny JR, Chen L, McGinnity DF, Grime K, Shakesheff KM, Thomson B, Riley R, Xenobiotica 2008 38 1500 1517 10.1080/00498250802495846 18989830
22. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ, Drug Metab Dispos 2006 34 1291 1300 10.1124/dmd.106.009969 16679385
23. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y, Br J Clin Pharmacol 2010 69 656 662 10.1111/j.1365-2125.2010.03624.x 20565457
24. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Qin WJ, Zhang W, Liu ZQ, Chen XP, Tan ZR, Hu DL, Wang D, Fan L, Zhou HH, Br J Clin Pharmacol 2012 74 999 1004 10.1111/j.1365-2125.2012. 04304.x 22519658
25. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Kim H, Bae SK, Park SJ, Shim EJ, Kim HS, Shon JH, Liu KH, Shin JG, Br J Clin Pharmacol 2010 70 126 131 10.1111/j.1365-2125.2010.03661.x 20642555
26. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. Nordmark A, Andersson A, Baranczewski P, Wanag E, Ståhle L, Eur J Clin Pharmacol 2014 70 167 178 10.1007/s00228-013-1603-8 24186263
27. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M, Mol Pharmacol 2005 67 1954 1965 10.1124/mol.104.009019 15761118